Çѱ¹½ÉÃÊÀ½ÆÄÇÐȸ Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ The Pulse of Asia in 2009

2009³â 4¿ù 17ÀÏ (±Ý) : D1
Á¦1ȸÀÇÀå
Á¦2ȸÀÇÀå
Á¦3ȸÀÇÀå
Á¦4ȸÀÇÀå
Á¦5ȸÀÇÀå
08:30-10:00 Oral Presentation ¥° Interesting ECG Epidemiology in Lipid &
Atherosclerosis
Controversies in Pediatric
Heart Disease
10:00-10:30 Coffee break
10:30-12:30 Young Investigator
Award & ¿¬±¸ºñ¹ßÇ¥


Oral Presentation ¥±
Catheter Ablation
Technology
Evaluation of
Atherosclerosis and
Vascular Disease
(10:30-12:10)
Çмú¿¬±¸ºñ ¹ßÇ¥
(12:10-12:30)
Recent Advance in Fetal
Cardiology
12:30-14:00 Satellite Symposium1
GSK
Satellite Symposium2
Sanofi-aventis
Satellite Symposium3
Áß¿ÜÁ¦¾à
Satellite Symposium 4
Çѵ¶¾àǰ
14:00-16:00 Echo in Clinical Practice
/ Case Studies
Update in Interventional
Cardiology
Dyslipidemia, Other than
Hypercholesterolemia
Recent Advance in
Pediatric CHF
16:00-16:30 Coffee break 16:00-17:00
Plenary Session
17:00-18:30
How to find unhealthy pulse?
16:30-18:30 Dilemma in Clinical
Practice: What Echo Can Help
/ ½ÉÃÊÀ½ÆÄ °ü·Ã ÃÖ½ÅÁö°ß
Debate in Interventional
Cardiology
New Insights into
Generation of
Atherosclerosis
Advance in Pediatric
Cardiac Surgery
2009³â 4¿ù 18ÀÏ (Åä) : D2
Á¦1ȸÀÇÀå
Á¦2ȸÀÇÀå
Á¦3ȸÀÇÀå
Á¦4ȸÀÇÀå
Á¦5ȸÀÇÀå
08:30-10:00 Advance in International
Technology and Device 1
Novel Targets in
AF Management
Evaluation of
Atherosclerosis
Heart Failure with
Preserved Ejection Fraction
08:30-10:10
Molecular and hemorheologic approach in vascular disease
10:00-10:30 Coffee break
10:30-12:00 Advance in International
Technology and Device 2
Sudden Cardiac Death New Insights for PPAR
Agonist : Good and Bad Aspect
Heart Failure with
Co-Morbidities
10:30-12:10
Pulse and cardiovascular risk
12:00-12:40 ¼­¼ø±Ô ±³¼ö ±â³ä Ư°­ 12:10-13:30
Central blood pressure management
- time for use in clinical practice?
12:40-14:00 Satellite Symposium 5
Boehringer Ingelheim & GSK
Satellite Symposium6
Çѱ¹´ÙÀÌÀÌÂî»êÄì/´ë¿õÁ¦¾à
Satellite Symposium 7
Merck Serono
Satellite Symposium 8
Çѱ¹MSD
14:00-15:30
Newer finding on vascular disease
14:00-16:00 Hypertension in Metabolic Syndrome CRT Stem Cell Biology Review Multimodality Imaging
for the 'Viability'
15:50-17:10
Clinical experience of arterial function

2009³â ¼øÈ¯±â°ü·ÃÇÐȸ Ãá°èÅëÇÕÇмú´ëȸ - ´ëÇѽÉÀåÇÐȸ -
4¿ù 17ÀÏ(±Ý)
- Á¦ 2ȸÀÇÀå -
08:30~10:00 Interesting ECG ÁÂÀå : ±è¿µÈÆ, ½Åµ¿±¸
Panel: ±èÁØ, ±èÁø¹è, ³²±ÃÁØ, ½Å´ëÈñ, ÀÓÈ«ÀÇ, Çö´ë¿ì
10:30~12:30 Catheter Ablation Technology ÁÂÀå : ÃÖÀ±½Ä, Á¶Á¤°ü
10:30-10:55 1. RF Energy Monitoring During Ablation ¿À¼¼ÀÏ/¼­¿ïÀÇ´ë
10:55-11:20 2. New Energy Sources and Catheters for Ablation circulation_42_1129_200901.pdf ÃÖ±âÁØ/¿ï»êÀÇ´ë
11:20-11:45 3. New Approaches to Unusual Targets ¹ÚÈñ³²/¿¬¼¼ÀÇ´ë
11:45-12:10 4. Image Integration & Catheter Navigation Technology circulation_42_1131_200901.pdf ¿À¿ë¼®/°¡Å縯ÀÇ´ë
12:10-12:30 5. Panel Discussion Panel: À̸¸¿µ, À̹®Çü
14:00~16:00 Update in Interventional Cardiology ÁÂÀå : ½É¿øÈì, ±è¿µÁ¶
14:00-14:20 1. Immediate Beta Blockade in STEMI Patients : Is It Really Helpful? circulation_43_1133_200901.pdf ±è ¿ø/°æÈñÀÇ´ë
14:20-14:40 2. Immediate Statin in STEMI Patients : Is It Really Helpful? circulation_43_1134_200901.pdf ¹ÚÁ¾¼±/¿µ³²ÀÇ´ë
14:40-15:00 3. Contrast-Induced Nephropathy, Prognostic Implication & Prevention; Current Status circulation_43_1135_200901.pdf Á¶»óÈ£/ÇѸ²ÀÇ´ë
15:00-15:20 4. Plavix Resistance, Cause & Clinical Implication: Current Status circulation_43_1136_200901.pdf ¼­Á¤¿ø/¼­¿ïÀÇ´ë
15:20-15:40 5. Recent Clinical Data of 3rd Generation DES circulation_43_1137_200901.pdf ¹èÀåÈ£/°Ç¾çÀÇ´ë
15:40-16:00 6. Panel Discussion
Panel: ±è¹«Çö, ±èÁ¾Áø, ±èÈ¿¼ö, ¹Ú¼º¿í, ¼ºÀÎȯ, ¾È¿µ±Ù, ¾ÈÅÂÈÆ, Àå¾ç¼ö
16:30~18:30 Debate in Interventional Cardiology ÁÂÀå : ½ÅÀͱÕ, ±è±Ç¹è
In certain patients with Stable Angina
16:30-16:42 1. Medical Treatment is Better circulation_44_1139_200901.pdf ÀÌöȯ/¿ï»êÀÇ´ë
16:42-16:54 2. PCI is Better circulation_44_1140_200901.pdf ±è¸í°ï/°æÈñÀÇ´ë
16:54-17:00 3. Panel Discussion Panel: ¾çÁÖ¿µ, ¿¬ÅÂÁø, ÃÖµ¿ÈÆ
In Certain Patients with Multi-vessel Disease
17:00-17:12 1. CABG is Better circulation_44_1142_200901.pdf ¹èÀåȯ/ÃæºÏÀÇ´ë
17:12-17:24 2. PCI is Better circulation_44_1143_200901.pdf Çö¹Î¼ö/¼øÃµÇâÀÇ´ë
17:24-17:30 3. Panel Discussion Panel: ±è¿µ´ë, ½Â±â¹è, Àüµ¿¿î
In Certain Patients with Left Main Disease
17:30-17:42 1. CABG is Better circulation_44_1145_200901.pdf ±è±âºÀ/¼­¿ïÀÇ´ë
17:42-17:54 2. PCI is Better circulation_44_1146_200901.pdf È«¸í±â/¿¬¼¼ÀÇ´ë
17:54-18:00 3. Panel Discussion Panel: ±èº´±Ø, ³ª½Â¿î, ¹Ú±Ý¼ö
In Certain Patients with CTO
18:00-18:12 1. Medical is Better circulation_44_1148_200901.pdf ±è¿µÇÐ/¿ï»êÀÇ´ë
18:12-18:24 2. Revascularization is Better circulation_44_1149_200901.pdf À̳»Èñ/¼øÃµÇâÀÇ´ë
18:24-18:30 3. Panel Discussion Panel: ¹ÚÇå½Ä, ÀÌÀçȯ, Á¤¸íÈ£
- Á¦ 4ȸÀÇÀå -
08:30~10:00 Controversies in Pediatric Heart Disease ÁÂÀå : ³ëÁ¤ÀÏ, ÀÌÁÖ¿ø
08:30-08:50 1. Adult Congenital Heart Disease circulation_45_1151_200901.pdf ÇãÁØ/¼º±Õ°üÀÇ´ë
08:50-09:10 2. Screening for Sudden Death in Childhood and Adolescents circulation_45_1152_200901.pdf ±è³²¼ö/ÇѾçÀÇ´ë
09:10-09:30 3. Obseity and Heart Disease in Childhood and Adolescents circulation_45_1153_200901.pdf È«¿µ¹Ì/ÀÌÈ­ÀÇ´ë
09:30-09:50 4. Medical Treatment in Myocarditis and Cardiomyopathy circulation_45_1154_200901.pdf ±è¿©Çâ/°è¸íÀÇ´ë
09:50-10:00 5. Panel Discussion Panel: ¼Û¿µÈ¯, À̵¿¼®, Áø¼±¹Ì
10:30~12:30 Recent Advance in Fetal Cardiology ÁÂÀå : ÀÌÈïÀç, ¼º½ÃÂù
10:30-10:50 1. The Role of the Fetal Cardiologist in Non-cardiac Fetal Conditions circulation_46_1156_200901.pdf À±½Å¿ø/Áß¾ÓÀÇ´ë
10:50-11:10 2. Heart Failure in the Fetus circulation_46_1157_200901.pdf ¼Û¹Î¼·/ÀÎÁ¦ÀÇ´ë
11:10-11:30 3. Fetal Cardiovascular Physiology: Characterization by Echocardiography Á¤Á¶¿ø/¾ÆÁÖÀÇ´ë
11:30-11:50 4. Current Status of Fetal Surgical Intervention circulation_46_1159_200901.pdf ÀÌÁ¤·Ä/¼­¿ïÀÇ´ë
11:50-12:10 5. Organizing a Comprehensive Fetal Cardiology Program circulation_46_1160_200901.pdf ¿øÇý¼º/¿ï»êÀÇ´ë
12:10-12:30 6. Panel Discussion Panel: °­¼öÁ¤, ¹ÚÁ¤ÁØ, Àº¿µ¹Î
14:00~16:00 Recent Advance in Pediatric CHF ÁÂÀå : ¿ÀºÀ¼®, ÀÌ»ó¹ü
14:00-14:20 1. Diagnosis and Classification circulation_47_1162_200901.pdf ÃÖÀ翵/¿¬¼¼ÀÇ´ë
14:20-14:40 2. Medical Management circulation_47_1163_200901.pdf ±è¼öÁø/ºÎõ¼¼Á¾º´¿ø
14:40-15:00 3. Electrophysiology Management : Biventricular Pacing and ICD circulation_47_1164_200901.pdf Çö¸íö/°æºÏÀÇ´ë
15:00-15:20 4. Mechanical Circulatory Support circulation_47_1165_200901.pdf ±è½ÃÈ£/µ¿¾ÆÀÇ´ë
15:20-15:40 5. Surgical Strategies for the Failing Systemic Ventricle circulation_47_1166_200901.pdf À±ÅÂÁø/¿ï»êÀÇ´ë
15:40-16:00 6. Panel Discussion Panel: ¾çÁöÇõ, ¿ìÇâ¿Á, ¹ÝÁöÀº
16:30-18:30 Advance in Pediatric Cardiac Surgery ÁÂÀå : ±è¿ëÁø, À̱¤¼÷
16:30-16:50 1. Current Strategy for RVOT Reconstruction circulation_48_1168_200901.pdf ¹ÚÇѱâ/¿¬¼¼ÀÇ´ë
16:50-17:10 2. Strategy for Improving Neurologic OutcomeAfter Congenital Cardiac Surgery circulation_48_1169_200901.pdf ¹ÚÁ¤ÁØ/¿ï»êÀÇ´ë
17:10-17:30 3. Neonatal Repair vs. Staged Repair in Pulmonary Atresia with VSD circulation_48_1170_200901.pdf ¾çÁöÇõ/¼º±Õ°üÀÇ´ë
17:30-17:50 4. Arrhythmia Surgery in Single Ventricle circulation_48_1171_200901.pdf ±è¿õÇÑ/¼­¿ïÀÇ´ë
17:50-18:10 5. Modifications of Fontan Procedure to Reduce Pulmonary Arteriovenous Malformations circulation_48_1172_200901.pdf ÀÓÈ«±¹/ºÎõ¼¼Á¾º´¿ø
18:10-18:30 6. Panel Discussion Panel: ¹Ú¿µÈ¯, ¼­µ¿¸¸, ¼º½ÃÂù
4¿ù 18ÀÏ(Åä)
- Á¦ 1ȸÀÇÀå -
08:30~10:00 Advance in Interventional Technology and Device 1 ÁÂÀå : Á¶½Â¿¬, ¹Ú½ÂÁ¤
08:30-08:45 1. OCT circulation_49_1174_200901.pdf Á¶Áø¸¸/°æÈñÀÇ´ë
08:45-09:00 2. Cardiac MRI ÀÌ »ó/À»ÁöÀÇ´ë
09:00-09:15 3. Myocardial CT Imaging circulation_49_1176_200901.pdf ±èÀ±Çö/Àü³²ÀÇ´ë
09:15-09:30 4. IVUS & VH circulation_49_1177_200901.pdf °í¿µ¿±/Á¶¼±ÀÇ´ë
09:30-09:45 5. FFR & CFR circulation_49_1178_200901.pdf À±¸íÈ£/¾ÆÁÖÀÇ´ë
09:45-10:00 6. Panel Discussion
Panel: ±¸º»±Ç, À±Á¤ÇÑ, ÀÌ»óÈÆ, äÁ¦°Ç, ÃÖ¿µÁø, ÃÖÁøÈ£, ʽÂÁ¦, È«¿µÁØ, È«ÅÃÁ¾
10:30~12:00 Advance in Interventional Technology and Device 2 ÁÂÀå : ¹Ú¿µ¹è, ÀÌ»óÈÆ
10:30-10:45 1. Myocardial Salvage in AMI-Preconditioning, Postconditioning circulation_50_1180_200901.pdf ±èµÎÀÏ/ÀÎÁ¦ÀÇ´ë
10:45-11:00 2. PCPS circulation_50_1181_200901.pdf ÇÑÁÖ¿ë/¼º±Õ°üÀÇ´ë
11:00-11:15 3. EVAR (AAA and Aortic Dissection) circulation_50_1182_200901.pdf °í¿µ±¹/¿¬¼¼ÀÇ´ë
11:15-11:30 4. Drug Eluting Balloon ¹Ú°æ¿ì/¼­¿ïÀÇ´ë
11:30-11:45 5. Next Generation DES circulation_50_1184_200901.pdf ÀÌÁØÈñ/ÇѸ²ÀÇ´ë
11:45-12:00 6. Panel Discussion
Panel: ±ÇÇöö, ÀÌ»ó°ï, À̽Âȯ, Á¶¿µ¼®, Á¤¿í¼º, Â÷±¤¼ö, ÃÖ½ÂÇõ, ÇѱԷÏ, Çã½ÂÈ£
12:00~12:40 ¼­¼ø±Ô ±³¼ö ±â³äƯ°­ ÁÂÀå : ½ÉºÀ¼·
12:00-12:40 Molecular Control of Vascular Development Anne Eichmann/College de France, France
14:00-16:00 Hypertension in Medtabolic Syndrome ÁÂÀå : È«¼øÇ¥, ±èöȣ
14:00-14:20 1. Epidemiologic and Physiologic Relevance of Surrogate Markers for CV Events circulation_52_1187_200901.pdf ÃÖ½ÂÇõ/¼º±Õ°üÀÇ´ë
14:20-14:40 2. Inflammation in Hypertension and Metabolic Syndrome circulation_52_1188_200901.pdf ±èÀÀÁÖ/°í·ÁÀÇ´ë
14:40-15:00 3. Aging or Insulin Resistance in Hypertension and Metabolic Syndrome circulation_52_1189_200901.pdf ±è±¤ÀÏ/¼­¿ïÀÇ´ë
15:00-15:20 4. How to Stop the Progression of Metabolic Syndrome to CV Events circulation_52_1190_200901.pdf À̹«¿ë/µ¿±¹ÀÇ´ë
15:40-16:00 5. Panel Discussion Panel: °í±¤°ï, ±è¿µ±Ç, ¹Úâ±Ô, ¼º±âö, Â÷ºÀ¼ö
- Á¦ 2ȸÀÇÀå -
08:30-10:00 Novel Targets in AF Management ÁÂÀå : ±è¼º¼ø, ¿Àµ¿Áø
08:30-08:50 1. Pathophysiology of AF circulation_53_1193_200901.pdf ³²±âº´/¿ï»êÀÇ´ë
08:50-09:10 2. Pharmacological Therapy for Substrate Modification circulation_53_1194_200901.pdf °ûÃæÈ¯/°æ»óÀÇ´ë
09:10-09:30 3. New Antithrombotic Drugs circulation_53_1195_200901.pdf À̸í¿ë/´Ü±¹ÀÇ´ë
09:30-09:50 4. New Antiarrhythmic Drugs circulation_53_1196_200901.pdf ¹Ú°æ¹Î/ÀÎÁ¦ÀÇ´ë
09:50-10:00 5. Panel Discussion Panel: ±è´ë°æ, ±èÁø¼®, Á¤º´Ãµ
10:30-12:00 Sudden Cardiac Death ÁÂÀå : ³ëÅÂÈ£, ÃÖÀμ®
10:30-10:50 1. Noninvasive Assessment of SCD Risk in Patients with Structural Heart Disease circulation_54_1198_200901.pdf ½Åµ¿±¸/¿µ³²ÀÇ´ë
10:50-11:10 2. Role of EPS in the Evaluation of High-Risk Patients for SCD circulation_54_1199_200901.pdf Â÷ÅÂÁØ/°í½ÅÀÇ´ë
11:10-11:30 3. Management of Channelopathy Including LQTS and Brugada Syndrome circulation_54_1200_200901.pdf Á¶¿ë±Ù/°æºÏÀÇ´ë
11:30-11:50 4. ICD for Primary Prevention circulation_54_1201_200901.pdf ±è³²È£/¿ø±¤ÀÇ´ë
11:50-12:00 5. Panel Discussion Panel: ±èÁؼö, ÀÌ¿µ¼ö, Á¤ÁßÈ­
14:00-16:00 CRT ÁÂÀå : ±èÀ¯È£, ±èÀ±³â
14:00-14:20 1. Evaluation of Dyssynchrony Á¶±¸¿µ/¼­¿ïÀÇ´ë
14:20-14:40 2. Role of CT and MRI for CRT Candidates ÀÌ»óö/¼º±Õ°üÀÇ´ë
14:40-15:00 3. Predictors of CRT Response circulation_55_1205_200901.pdf ¹ÚÇü¿í/Àü³²ÀÇ´ë
15:00-15:20 4. Current & Emerging Indications of CRT circulation_55_1206_200901.pdf À̰漮/ÀüºÏÀÇ´ë
15:20-15:40 5. Technical Aspects of CRT Device Implantation circulation_55_1207_200901.pdf ¹Ú»ó¿ø/°í·ÁÀÇ´ë
15:40-16:00 6. Panel Discussion Panel: Á¶¿ë±Ù, Ȳ±³½Â
- Á¦ 3ȸÀÇÀå -
08:30~10:00 Evaluation of Atherosclerosis ÁÂÀå : ½ÅÇöÈ£, ±èÄ¡Á¤
08:30-08:50 1. Gene and Atherosclerosis circulation_56_1209_200901.pdf ¹ÚÇö¿µ/±¹¸³º¸°Ç¿ø
08:50-09:10 2. Biomarker of Atherosclerosis circulation_56_1210_200901.pdf ¿À¼®±Ô/¿ø±¤ÀÇ´ë
09:10-09:30 3. Imaging of Atherosclerosis circulation_56_1211_200901.pdf ±è¿ëÁø/¼­¿ïÀÇ´ë
09:30-09:50 4. Primary Prevention of Atherosclerosis circulation_56_1212_200901.pdf ÇѱâÈÆ/¿ï»êÀÇ´ë
09:50-10:00 5. Panel Discussion Panel: ±èÀ念, ¼­È«¼®, ¼ºÁöµ¿, ±è»óÇö, ÇѽÂȯ
10:30~12:00 New Insigt for PPAR Agonist : Good and Bad Aspect ÁÂÀå : ¹ÚÁ¤ÀÇ, ·ù¿Õ¼º
10:30-10:50 1. PPAR¥ã Agonists and Diabetes Control circulation_57_1214_200901.pdf ¿ìÁ¤ÅÃ/°æÈñÀÇ´ë
10:50-11:10 2. PPAR¥ã Regulates Insulin Sensitivity and Atherosclerosis ¹Ú°æ¼ö/¼­¿ïÀÇ´ë
11:10-11:30 3. PPAR¥ã Agonists and CV Mortality circulation_57_1216_200901.pdf È«¼øÁØ/°í·ÁÀÇ´ë
11:30-11:50 4. PPAR¥ä Agonist and Vasculogenesis circulation_57_1217_200901.pdf ÇÑÁ¤±Ô/¼­¿ïÀÇ´ë
11:50-12:00 5. Panel Discussion Panel: À̹®±Ô, ÀÓ¼ö, Â÷ºÀ¼ö, ÇѱâÈÆ, ȲÁø¿ë
14:00~16:00 Stem Cell Biology Review ÁÂÀå : ÀüÀº¼®, ±èÈ¿¼ö
14:00-14:25 1. Induced Pluripotent Stem Cells; Review of Current Status circulation_58_1219_200901.pdf Á¶ÇöÀç/¼­¿ïÀÇ´ë
14:25-14:50 2. Vasculogenic Progenitor Cells; Review of Current Status circulation_58_1220_200901.pdf Á¤Çü¹Î/Â÷¹ÙÀÌ¿ÀÅØ
15:50-15:15 3. Hematopoietic Stem Cells ; Review of the Current Status circulation_58_1221_200901.pdf ¾öÇö¼®/±¹¸³¾Ï¼¾ÅÍ
15:15-15:40 4. Cardiomyogenic & Adipose Stem Cells ; Review of the Current Status ¹é»óÈ«/Ä«Å縯ÀÇ´ë
15:40-16:00 5. Panel Discussion Panel: °­ÇöÀç, ±è°æ¼ö, ¾È¿µ±Ù, ÀÓµµ¼±
- Á¦ 4ȸÀÇÀå -
08:30-10:00 Heart Failure with Preserved Ejection Fraction ÁÂÀå : ¿Àº´Èñ, Á¶¸íÂù
08:30-08:55 1. Clinical Implication and Pathophysiology circulation_59_1224_200901.pdf ±èµ¿¿î/ÃæºÏÀÇ´ë
08:55-09:20 2. How to Make a Diagnosis circulation_59_1225_200901.pdf ¹Ú´ë±Õ/ÇѸ²ÀÇ´ë
09:20-09:45 3. Which Drug is Choice of Treatment circulation_59_1226_200901.pdf ±èÇü¼·/°è¸íÀÇ´ë
09:45-10:00 4. Panel Discussion Panel: ±èµ¿¼ö, ±è¿µ±Ç, ¹é»óÈ«, Á¤¿íÁø
10:30-12:00 Heart Failure with Co-Morbidities ÁÂÀå : ÀÌ¸í¹¬, À¯±ÔÇü
10:30-10:50 1. Obesity in Heart Failure circulation_60_1228_200901.pdf °­¼®¹Î/¿¬¼¼ÀÇ´ë
10:50-11:10 2. Diabetes in Heart Failure circulation_60_1229_200901.pdf ÁÖ½ÂÀç/Á¦ÁÖÀÇ´ë
11:10-11:30 3. Inflammatory Cytokines in Heart Failure circulation_60_1230_200901.pdf ÇѼº¿ì/°Ç±¹ÀÇ´ë
11:30-11:50 4. Nutrition in Heart Failure circulation_60_1231_200901.pdf ½Å¹ÎÁ¤/°í·Á´ëÇб³
11:50-12:00 5. Panel Discussion Panel: ±è¸í¾Æ, ¹ÚÀçÇü, ÀüÀº¼®, Á¶¸íÂù, ÃÖµ¿ÁÖ
14:00~16:00 Multimodality Imaging for the 'Viability' ÁÂÀå : ÀÓÅÂȯ, ¼Õ´ë¿ø
14:00-14:20 1. Viability : Clinical Significance ¹Ú½Â¿ì/¼º±Õ°üÀÇ´ë
14:20-14:40 2. SPECT circulation_61_1234_200901.pdf °­¿øÁØ/¿¬¼¼ÀÇ´ë
14:40-15:00 3. CT circulation_61_1235_200901.pdf ¹ÚÀº¾Æ/¼­¿ïÀÇ´ë
15:00-15:20 4. Echo circulation_61_1236_200901.pdf ¼ÛÁ¾¹Î/¿ï»êÀÇ´ë
15:20-15:40 5. MRI circulation_61_1237_200901.pdf Á¤Á¤ÀÓ/°¡Å縯ÀÇ´ë
15:40-16:00 6. Panel Discussion Panel: ÀåÇõÀç, ¿ëȯ¼®, ÀÌÁ¾¹Î
* Satellite Symposium
4¿ù 17ÀÏ(±Ý)
- Á¦ 1ȸÀÇÀå -
GSK - The Latest Vasodilating Beta Blocker : From Hypertension to Heart Failure ÁÂÀå : Á¶½Â¿¬, ÀÌ¸í¹¬
Action Mechanisms of Nebivolol; Nitric Oxide-releasing and Vasodilating circulation_62_1298_200901.pdf ±èÈ¿¼ö/¼­¿ïÀÇ´ë
Role of Beta Blocker in Elderly Heart Failure circulation_62_1299_200901.pdf ÀüÀº¼®/¼º±Õ°üÀÇ´ë
- Á¦ 2ȸÀÇÀå -
Sanofi-aventis - New Perspectives in the Management of Cardiovascular Diseases ÁÂÀå : ¿Àº´Èñ, Àå¾ç¼ö
RAS Blockade on Atrial Fibrillation; A Dream? circulation_63_1295_200901.pdf ¹ÚÁ¤¹è/°üµ¿ÀÇ´ë
The Role of Antiplatelet Therapy in the Era of Drug Eluting Stents Cindy L. Grines/Beaumont Hospital, USA
- Á¦ 3ȸÀÇÀå -
Áß¿ÜÁ¦¾à - New Concept of Metabolic Syndrome and Beyond with Statin ÁÂÀå : ±è´ö°æ, Á¤¸íÈ£
Chiba Study Kohji Shirai/School of Medicine Toho Univ., Japan
±Þ¼º ½É±Ù°æ»öÁõ ȯÀÚ¿¡¼­ Statin »ç¿ëÀ¸·Î Àú¹Ðµµ Áö´Ü¹é ÄÝ·¹½ºÅ×·Ñ ¸ñǥġ¿¡ÀÇ µµ´Þ°ú ¿¹ÈÄ¿ÍÀÇ °ü°è circulation_64_1292_200901.pdf È«¿µÁØ/Àü³²ÀÇ´ë
Safety and Efficacy of Statin in Patients with Acute Myocardial Infarction in an Asian Population circulation_64_1293_200901.pdf ³ª½Â¿î/°í·ÁÀÇ´ë
- Á¦ 4ȸÀÇÀå -
Çѵ¶¾àǰ - Early Action in Pulmonary Arterial Hypertension ÁÂÀå : Á¤³²½Ä, ¼Õ´ë¿ø
Æó°íÇ÷¾ÐÀÇ ºÐ·ù¿Í Áø´Ü ¹× Æò°¡ circulation_65_1287_200901.pdf ÀåÇõÀç/¿¬¼¼ÀÇ´ë
The Future of Pulmonary Arterial Hypertension (PAH) Management -Building on the Evidence Nazzareno Galie/Univ. of Bolona, Italy
4¿ù 18ÀÏ(Åä)
- Á¦ 1ȸÀÇÀå -
Boehringer Ingelheim & GSK- A New Era of Cardio & Vascular Protection Treatment with High Risk Patients ÁÂÀå : ±èÀçÇü, ¿Àµ¿ÁÖ
New Evidences in 24hr Blood Pressure Lowering Effect of Telmisartan in Comparative Trials circulation_66_1285_200901.pdf 伺ö/°æºÏÀÇ´ë
ONTARGET : Asian Tolerability circulation_66_1286_200901.pdf ¼­È«¼®/°í·ÁÀÇ´ë
- Á¦ 2ȸÀÇÀå -
Çѱ¹´ÙÀÌÀÌÂî»êÄì/´ë¿õÁ¦¾à - Optimizing Synergistic Effect of CCB/ARB Combination Therapy ÁÂÀå : ¹Ú¿µ¹è, Á¤¸íÈ£
How to Manage Hypertensive Patients Who Fail to Achieve BP Goal? circulation_67_1283_200901.pdf ±èÈ¿¼ö/¼­¿ïÀÇ´ë
Combined Therapy with CCB and ARB: A New Combination Treatment Option to Better Control Hypertension Franz Messerli/St. Lukes-Roosevelt Hospital Center, USA
- Á¦ 3ȸÀÇÀå -
Merck Serono - Cardiovascular Diseases: Where Highly ¥â-1 Selective Blockers Must be Used ÁÂÀå : À¯±ÔÇü, ½Â±â¹è
Clinical Benefits of ¥â-blockers in Hypertension & Heart Failure circulation_83_1281_200901.pdf ÃÖµ¿ÁÖ/¼­¿ïÀÇ´ë
Proven Benefits of ¥â-blockers in Ischemic Heart Disease circulation_83_1282_200901.pdf ÀÌöȯ/¿ï»êÀÇ´ë
- Á¦ 4ȸÀÇÀå -
Çѱ¹MSD - New Management of Cardiometabolic Disease ÁÂÀå : ÀÌ¿ø·Î, ¹ÚÁ¤ÀÇ
A New Paradigm in the Treatment of Type 2 Diabetes circulation_84_1279_200901.pdf ¹é»óÈ«/°¡Å縯ÀÇ´ë
Dual Benefits by Lowering 2 Source of Atherogenic Cholesterol circulation_84_1280_200901.pdf ±è»óÇö/¼­¿ïÀÇ´ë



2009³â ¼øÈ¯±â°ü·ÃÇÐȸ Ãá°èÅëÇÕÇмú´ëȸ - Çѱ¹½ÉÃÊÀ½ÆÄÇÐȸ -
4¿ù 17ÀÏ(±Ý) [Á¦ 1ȸÀÇÀå]
08:30-10:30 Oral Presentation ¥° ÁÂÀå : Á¤»ó¸¸, ÁÖ½ÂÀç
08:30-08:40 Left Atrial Vlume Idex as a Powerful Pedictor of Adverse Outcome in Patients with Hypertrophic Cardiomyopathy ¾ç¿ìÀÎ/¿¬¼¼ÀÇ´ë
08:40-08:50 Acute Myocardial Infarction Without Wall Motion Abnormality in Initial Echocardiography : Clinical Outcome and Predictors of Left Ventricular Dysfunction After 1 Year Follow Up °íÁ¡¼®/ÀüºÏÀÇ´ë
08:50-09:00 Geometric Changes and Predictors of Residual Tricuspid Regurgitation After Tricuspid Annuloplasty: A Real-Time 3-Dimensional Echocardiography Study ¹Î¼±¾ç/¿ï»êÀÇ´ë
09:00-09:10 Evaluation of Right Ventricular Function in Patients with Acute Pulmonary Thromboembolism Using Velocity Vector Imaging ±è¼Ò¿¬/´ë±¸°¡Å縯ÀÇ´ë
09:10-09:20 The Safety and Feasibility of Bicycle Exercise Echocardiography in the Prediction of the Recovery of Left Ventricular Function in Patients with Acute Myocardial Infarction ¼­Çý¼±/¼øÃµÇâÀÇ´ë
09:20-09:30 Relation of Anemia to Diastolic Dysfunction in Hypertensive Patients Over 50 Year-Old ±èÀ¯¸®/ÀÌÈ­ÀÇ´ë
09:30-09:40 Comparison of Regional Wall Motion in Patients With Stress Induced Cardiomyopathy and Acute Myocardial Infarction by Velocity Vector Imaging Á¤Áø¿í/´ë±¸°¡Å縯ÀÇ´ë
09:40-09:50 Incremental Value of the Carotid Ultrasound in Patients with Chronic Hemodialysis ÀÌ¿ø±¸/ºÎ»êÀÇ´ë
09:50-10:00 Clinical Characteristics of Stress-Induced Cardiomyopathy: Single Center Exprience ÀÌÁØ¿ø/¿øÁÖÀÇ´ë
10:00-10:10 The Predictors of left Ventricular Dyssynchrony in Patients Underwent Implantation of Permanent Pacemaker À̹α¸/Àü³²ÀÇ´ë
10:30-11:30 Young Investigator Award & ¿¬±¸ºñ¹ßÇ¥ ÁÂÀå : ½Å±æÀÚ, ±Ç ÁØ
10:30-10:45 Relationship between Untwisting Velocity and Invasively Measured Diastolic Function Parameters ±è´ëÈñ/¿ï»êÀÇ´ë
10:45-11:00 Deceleration Time of the Left Ventricular Outflow Tract Flow Velocity: A Surrogate Doppler Echocardiographic Parameter for Central Pulse Pressure ½ÉÁö¿µ/¿¬¼¼ÀÇ´ë
11:00-11:15 Impact of Loading Conditions on the Left Ventricular Dyssynchrony in Non-Ischemic Dilated Cardiomyopathy : Assessment with Speckle Tracking-Based Radial Strain ¹ÚÈ¿Àº/¼­¿ïÀÇ´ë
11:15-11:30 Impact of Afterload on the Assessment of Aortic Stenosis À强¾Æ/¼º±Õ°üÀÇ´ë
[½É»çÀ§¿ø] ±è±â¿µ, ±è¿ëÁø, ¹Ú¼º¹Ì, ÀåÇõÀç, ÀüÈñ°æ, ÃÖÀÇ¿µ
11:30-12:30 Oral Presentation ¥± ÁÂÀå : À±È£Áß, ÀÓ¼¼Áß
11:30- 11:40 Does Left Atrial Volume Index Over Late Diastolic Mitral Annular Velocity (LAVi/A¡¯) Have Clinical Impact on Prediction of High LV Filling Pressure ? ÃÖ¿îÁ¤/¾ÆÁÖÀÇ´ë
11:40-11:50 Valsalva Maneuver to Predict Dynamic Intraventricular Obstruction During Dobutamine Stress Echocardiography in Patients with Hypertension ¼ÕÀϼ®/°æÈñÀÇ´ë
11:50-12:00 Predictors and Clinical Implication of LV Function Evolution after Percutaneous Coronary Intervention(PCI) in Acute Myocardial Infarction °íÁ¡¼®/Àü³²ÀÇ´ë
12:00-12:10 Complete Recovery of LV Systolic Function in Stress Induced Cardiomyopathy, Is it True? ±è¼Ò¿¬/´ë±¸°¡Å縯ÀÇ´ë
12:10-12:20 How Accurately Assess Left Ventricular Hypertrophy by Measurement of Wall Thickness in Patients with Untreated Hypertension ¼º¸íÁØ/´ë±¸°¡Å縯ÀÇ´ë
12:20-12:30 Usefulness of Mitral Annular Systolic Velocity in the Detection of Left Ventricular Systolic Dysfunction: Comparison with Three Dimensional Echocardiographic Data ¹ÚÀ±¼±/Ãæ³²ÀÇ´ë
Echo in Clinical Practice
14:00 - 14:20 Hemodynamics in Valve Disease °­´öÇö/¿ï»êÀÇ´ë
14:20 - 14:40 Evaluation of Regional Wall Motion Abnormality ½ÅÁØÇÑ/¾ÆÁÖÀÇ´ë
14:40 - 15:00 Pericardial Disease ÇÏÁ¾¿ø/¿¬¼¼ÀÇ´ë
Case Studies
15:00 - 15:15 Chest Pain ½Å¹Ì½Â/°¡ÃµÀÇ´ë
15:15 - 15:30 Shock À¯³²Áø/¿ø±¤ÀÇ´ë
15:30 - 15:45 Dyspnea ±èÀ念/¿øÁÖÀÇ´ë
15:45 - 16:00 Cardiomyopathy ¹ÚÅÂÈ£/µ¿¾ÆÀÇ´ë
Dilemma in Clinical Practice: What Echo Can Help
16:30 - 16:50 Asymptomatic MR, AR ±èÇü°ü/¼­¿ïÀÇ´ë
16:50 - 17:10 Therapeutic Guidance in HF ÃÖÁø¿À/¼º±Õ°üÀÇ´ë
17:10 - 17:30 Pulmonary HT in Congenital Heart Disease ±è¿ì½Ä/°æÈñÀÇ´ë
½ÉÃÊÀ½ÆÄ °ü·Ã ÃÖ½ÅÁö°ß
17:30 - 17:50 Vortex Imaging È«±×·ç/¿µ³²ÀÇ´ë
17:50 - 18:10 Clinical Application of 2D Speckle Tracking Imaging ±èÇü¼·/°è¸íÀÇ´ë
18:10 - 18:30 Real Time 3D Echo: TTE & TEE Á¤Çؾï/°¡Å縯ÀÇ´ë


2009³â ¼øÈ¯±â°ü·ÃÇÐȸ Ãá°èÅëÇÕÇмú´ëȸ - Çѱ¹ÁöÁúµ¿¸Æ°æÈ­ÇÐȸ Ãá°èÇмú´ëȸ -
4¿ù 17ÀÏ(±Ý)
08:20~08:30 Opening Remarks
08:30~10:00 Symposium I; Epidemiology in Lipid & Atherosclerosis ÁÂÀå : ±èÄ¡Á¤ (Áß¾ÓÀÇ´ë), ±èÇö¼÷ (¼÷¸í¿©´ë)
08:30 - 08:50 What Can We Learn about Diet and Heart Health from (East) Asian Emigrants? Ted Greiner/ÇѾç´ëÇб³
08:50 - 09:10 ÁöÁú ¼·Ãë¿Í ½ÉÇ÷°ü°èÁúȯ À§Çè¿äÀÎ : ±¹¹Î°Ç°­¿µ¾çÁ¶»ç °á°ú¸¦ Áß½ÉÀ¸·Î ¿À°æ¿ø/Áúº´°ü¸®º»ºÎ
09:10 - 09:30 Subclinical Atherosclerosis in Asymptomatic Subjects ÀÓ¼ö/¼­¿ïÀÇ´ë
09:30 - 09:50 Smoking Status and Metabolic Syndrome ±èº´Áø/¼º±Õ°üÀÇ´ë
09:50 - 10:00 Q&A Panel: ÀÌ»óÇÐ, ¹ÚÇö¿µ, ÀÌÇà½Å
10:30~12:10 Symposium II; Evaluation of Atherosclerosis and Vascular Disease ÁÂÀå : ¹Ú¿µ¹è (¼­¿ïÀÇ´ë), ½ÅÇöÈ£ (°üµ¿ÀÇ´ë)
10:30 - 10:50 Molecular Imaging of Atherosclerosis ¿©Á¤¼®/µ¿±¹ÀÇ´ë
10:50 - 11:10 Hemorheologic approach to Endothelial Function and Vascular Diseases Oguz K. Baskurt /Akdeniz Univ., Turkey
11:10~11:30 Atherosclerosis, Arteriosclerosis and Cerebral Microvascular Disease are Linked by the Arterial Pulse Michael O'Rourke /Univ. of New South Wales, Australia
11:30 - 11:50 Inflammation and Arterial Stiffness Carmel McEniery/Univ. of Cambridge, UK
11:50 - 12:10 Q&A Panel: ÇѱâÈÆ, ÇѽÂȯ, ¹ÚÁ¤¹è, ±èÀÀÁÖ
12:10~12:30 Çмú¿¬±¸ºñ ¹ßÇ¥ ÁÂÀå : Àå¾ç¼ö (¿¬¼¼ÀÇ´ë), ÃÖµ¿ÁÖ (¼­¿ïÀÇ´ë)
12:10 - 12:20 Korean Panax Red Ginseng decreases Rho-Associated Kinase Activity of Peripheral Blood Mononuclear Cells and Ameliorates Endothelial Dysfunction in Patients with Coronary Artery Disease Á¤À͸ð/ÀÌÈ­ÀÇ´ë
12:20 - 12:30 Role of PDE III inhibitor in the Differentiation of Adipocytes and Synthesis of Adipokine ¹Úö¿µ/¼º±Õ°üÀÇ´ë
12:30~14:00 Satellite Symposium
14:00~16:00 Symposium III; Dyslipidemia other than Hypercholesterolemia ÁÂÀå : ÀÌÁ¾È£ (¿¬¼¼´ë), ¿ìÁ¤Åà (°æÈñÀÇ´ë)
14:00 - 14:25 High Density Lipoprotein Cholesterol and Atherosclerosis ±è»óÇö/¼­¿ïÀÇ´ë
14:25 - 14:50 ³·Àº HDL ÄÝ·¹½ºÅ×·ÑÀÇ Ä¡·á(Treatment of low HDL-Cholesterol) ¼ºÁöµ¿/¼º±Õ°üÀÇ´ë
14:50 - 15:15 Omega-3 Fatty Acids in Cardiovascular Prevention ¹Ú¿ë¼ø/ÇѾç´ëÇб³
15:15 - 15:40 Modulation of Lipoprotein Metabolism by Sphingolipids ¹ÚŽÄ/°¡ÃµÀÇ´ë
15:40 - 16:00 Q&A Panel: ¼­È«¼®, ¹é»óÈ«, À̸í¼÷, ÃÖ¼ºÈñ
16:30~18:30 Symposium IV; New Insights into Generation of Atherosclerosis ÁÂÀå : Á¤ÇåÅà (¿ø±¤ÀÇ´ë), ±èÀç·æ (¿µ³²ÀÇ´ë)
16:30 - 16:50 Transcriptional Activation of HIF-1 by ROR¥á and Its Role in Hypoxia Signaling and New Blood Vessel Formation À̹̿Á/¼­¿ï´ëÇб³
16:50 - 17:00 Q&A
17:00 - 17:20 Cleavage and Functional Loss of Apolipoproteins by Matrix Metalloproteinases À̽ÂÅÃ/¿¬¼¼´ëÇб³
17:20 - 17:30 Q&A
17:30 - 17:50 4-Hydroxynonenal Contributes to Macrophage Foam Cell Formation through Increased Expression of Scavenger Receptors ±èÄ¡´ë/ºÎ»êÀÇ´ë
17:50 - 18:00 Q&A
18:00 - 18:20 Functional Role of Innate Immunity in Atherosclerosis ¹èÀ±¼ö/ÀÌÈ­¿©´ë
18:20 - 18:30 Q&A Panel: ¿À±¸ÅÃ, Á¶°æÇö, ÇÑÁø
18:30 - 18:40 Closing Remarks